|
| Index | - | P/E | - | EPS (ttm) | -248.68 | Insider Own | 2.09% | Shs Outstand | 1.55M | Perf Week | -11.55% |
| Market Cap | 4.23M | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | 0.87M | Perf Month | -25.56% |
| Income | -22.30M | PEG | - | EPS next Q | -1.40 | Inst Own | 2.00% | Short Float / Ratio | 8.44% / 0.14 | Perf Quarter | -51.54% |
| Sales | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Interest | 0.07M | Perf Half Y | -73.60% |
| Book/sh | -6.92 | P/B | - | EPS next Y | - | ROA | - | Target Price | 72.00 | Perf Year | -98.82% |
| Cash/sh | 0.89 | P/C | 3.02 | EPS next 5Y | - | ROE | - | 52W Range | 2.49 - 289.80 | Perf YTD | -56.27% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -99.08% | Beta | 1.69 |
| Dividend % | - | Quick Ratio | 1.40 | Sales past 5Y | - | Gross Margin | - | 52W Low | 7.63% | ATR | 0.32 |
| Employees | 17 | Current Ratio | 1.40 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 35.72 | Volatility | 10.20% 8.95% |
| Optionable | No | Debt/Eq | 0.22 | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.06 | Prev Close | 2.60 |
| Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 528.39K | Price | 2.68 |
| Recom | 2.00 | SMA20 | -15.31% | SMA50 | -31.35% | SMA200 | -83.48% | Volume | 29,267 | Change | 3.08% |
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite